- 1 Long-term gut colonization with ESBL-producing *Escherichia coli* in participants without known risk
- 2 <u>factors from the southeastern United States</u>
- 3 Coralis Rodriguez Garcia<sup>1</sup>, William A. Norfolk<sup>2a</sup>, Amanda K. Howard<sup>2,4</sup>, Amanda L. Glatter<sup>2b</sup>, Megan S.
- 4 Beaudry<sup>2c</sup>, Nicholas A. Mallis<sup>3</sup>, Michael Welton<sup>3</sup>, Travis C. Glenn<sup>2</sup>, Erin K. Lipp<sup>2</sup> and Elizabeth A.
- 5 Ottesen<sup>1#</sup>
- 6 <sup>1</sup> Department of Microbiology, University of Georgia, Athens, GA, USA
- 7 <sup>2</sup> Department of Environmental Health Sciences, University of Georgia, Athens, GA, USA
- 8 <sup>3</sup> Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA, USA
- 9 <sup>4</sup> Institute of Bioinformatics, University of Georgia, Athens, GA, USA
- 10 <sup>a</sup>Center for Disease Control and Prevention, Atlanta, Georgia, USA
- <sup>b</sup> Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT,
- 12 USA
- 13 <sup>c</sup> Daicel Arbor Biosciences, Ann Arbor, MI, USA
- 14 #Corresponding author.
- 15 Email: <u>ottesen@uga.edu</u>
- 16
- 17 Running Title: Gut colonization with ESBL-E. coli
- 18 Abstract

We evaluated gut carriage of extended spectrum beta lactamase producing *Enterobacteriaceae*(ESBL-E) in southeastern U.S. residents without recent in-patient healthcare exposure. Study enrollment
was January 2021-February 2022 in Athens, Georgia, U.S. and included a diverse population of 505
adults plus 50 child participants (age 0-5). Based on culture-based screening of stool samples, 4.5% of
555 participants carried ESBL-Es. This is slightly higher than reported in studies conducted 2012-2015,
which found carriage rates of 2.5-3.9% in healthy U.S. residents.

All ESBL-E confirmed isolates (n=25) were identified as *Escherichia coli*. Isolates belonged to 11 sequence types, with 48% classified as ST131. Ninety six percent of ESBL-E isolates carried a  $bla_{CTX}$ . *M* gene. Isolated ESBL-Es frequently carried virulence genes as well as multiple classes of antibiotic resistance genes. Long-term colonization was common, with 64% of ESBL-E positive participants testing positive when rescreened three months later. One participant yielded isolates belonging to two different *E*. *coli* sequence types that carried *bla*<sub>CTX-M-1</sub> genes on near-identical plasmids, suggesting intra-gut plasmid transfer.

Isolation of *E. coli* on media without antibiotics revealed that ESBL-*E. coli* typically made up a
 minor fraction of the overall gut *E. coli* population, although in some cases they were the dominant strain.
 ESBL-E carriage was not associated with a significantly different stool microbiome composition.

However, some microbial taxa were differentially abundant in ESBL-E carriers. Together, these results
suggest that a small subpopulation of US residents are long-term, asymptomatic carriers of ESBL-Es, and
may serve as an important reservoir for community spread of these ESBL genes.

#### 38 Importance

39 Antibiotic resistant bacteria, especially *Enterobacteriaceae* carrying ESBLs, have become an 40 increasing public health threat. Increasing numbers of community-associated infections (47% of ESBL-E 41 infections in the U.S.) in participants without healthcare exposure is particularly concerning. This study 42 found that 4.5% of a southeastern United States study population, without in-patient healthcare exposure, 43 were asymptomatically colonized with ESBL-E, and 64% of ESBL-E positive participants were still 44 positive when rescreened 3 months later. This suggests that the gut microbiome of healthy participants 45 may represent an understudied community reservoir of ESBL genes and ESBL Escherichia coli in the 46 U.S.

47 Keywords: extended-spectrum beta-lactamase, antimicrobial resistance, community-acquired ESBL,
48 microbiome, ESBL-*Enterobacteriaceae*

## 49 Introduction

Antimicrobial resistance is a serious and growing public health threat worldwide (1, 2) that contributes to increased complication rates, as well as increased treatment costs (3, 4). Extendedspectrum beta-lactamase (ESBL) producing *Enterobacteriaceae* (ESBL-E) are listed as a serious threat by the U.S. Center for Disease Control and Prevention (CDC), contributing to 197,400 infections and 9,100 deaths in 2019 (2).

55 ESBL-E were first reported in 1983 and have since spread rapidly throughout the world (5–8). ESBL 56 enzymes confer resistance to multiple antibiotics including penicillin, monobactams, and cephalosporins, 57 commonly used to treat infections caused by Gram negative bacteria (9). There are multiple classes of 58 ESBL enzymes including TEM, SHV, OXA and CTX-M (10–12). Recently, attention has been drawn to 59 the CTX-M class ESBLs as it is currently the most common ESBL found worldwide (13–16). CTX-M-15 60 is typically associated with E. coli sequence type 131 (ST131), a frequent causative agent of 61 extraintestinal infections and outbreaks (17, 18). The successful dissemination of this E. coli clone 62 contributed to the wide spread of this ESBL enzyme (19). Another factor contributing to the rapid 63 dissemination of ESBLs is their frequent association with mobile elements including plasmids (20–22). 64 Microorganisms often carry ESBL genes in plasmids from the groups IncF, IncI1, IncA/C and IncHI2, 65 facilitating horizontal gene transfer of antibiotic resistance (23). These plasmids also carry antibiotic 66 resistance genes for other classes, easily resulting in multi-drug resistant organisms (24).

67 In a meta-analysis by Bezabih et al. (25), the global intestinal carriage rate of ESBL-*E. coli* in the
68 community increased 10-fold during 2001-2020, highlighting the significance of investigating

69 community-associated ESBL-E. The global prevalence of ESBL-E fecal carriage in the community is 70 highly variable throughout the globe, with substantially higher rates (76.3%) in Tanzania and the lowest 71 (1.9%) in Australia (25, 26). The exact causes of these geographic variations are unknown, although they 72 have been associated to factors including the use of antibiotics in food animals and sanitation standards 73 (27).

74 Few studies have examined ESBL-E carriage in healthy individuals in the U.S. Doi et al. (28, 29) 75 reported a 3.9% prevalence of ESBL-E. coli in community-associated samples from outpatient clinics in 5 76 U.S. states collected in 2009-2010. Vento et al. (30) found that only 1 of 101 healthy U.S. military 77 personnel based in the U.S. (May-June 2011) carried an ESBL-E. Weisenberg et al. (31), reported a 2.5% 78 colonization rate for ESBL-E in 2012, among New York residents in participants at pre-travel or no 79 international travel planned. Finally, Islam et al. (32) reported an ESBL-E carriage rate of 3.5% among 80 stool samples from healthy children collected 2013-2015 in three U.S. cities. Overall, these studies 81 suggest that carriage of ESBL-E in the U.S. is low. However, the steady increase of community-82 associated ESBL-E infections from 2013-2019 (2, 29) suggest a need for updated data on ESBL-E 83 community carriage in the U.S.

The aim of this work, was an examination of the prevalence and risk factors for gut colonization of ESBL-E in the community among participants living in or near Athens, Georgia (GA), U.S. We also evaluated the frequency of long-term (~3 month) carriage of ESBL-E among positive participants. Finally, we performed an in-depth genomic analysis, including mobile elements, of ESBL-E isolated in this study and a comparison of gut microbiome community composition between carriers and noncarriers.

### 90 **Results**

We recruited a total of 555 participants including 505 adults and 50 children between January
2021 and November 2021 from the southeastern U.S. (mostly northeastern Georgia) (Fig. S1). Overall,
the study population reflected the demographic composition of the study area as expected based on U.S.
census data (Table S2), with some over-representation of participants who identified as white and nonHispanic, were 18-39 years of age, and/or reported female sex. (Table S1).

96 <u>Carriage of ESBL Enterobacteriaceae (ESBL-E)</u>

97 From 555 samples, 25 participants (4.5%) were positive for stool carriage of an ESBL-E. One of
98 the 25 ESBL-E positive participants was a child, whose parent also tested positive. Of the 25 ESBL-E
99 positive participants, 22 provided a second sample at follow-up (97-176 days later), including the parent100 child dyad. 14 of those 22 samples (64%) were ESBL-E positive, whereas the remaining 8 were ESBL-E
101 negative.

102 ESBL-E carriage was not identified as significantly associated with any of the demographic or 103 socioeconomic risk factors examined (Table 1, Table S1). We observed slightly, but not significantly, 104 increased incidence of ESBL-E in participants identified as biological males and Asian or Black/African 105 American race identities. The full list of occupational, lifestyle, and environmental risk factors tested is 106 available in supplemental table S1. A subset of the study population regularly experienced interaction 107 with increased risk environments; however, these exposures were not significantly associated with ESBL-108 E carriage. ESBL-E carriage was also not associated with significant differences in self-reported 109 gastrointestinal (GI) distress, urinary tract infection, or antibiotic usage. A review of the health 110 information provided by ESBL-E positive participants did not suggest severe chronic health problems.

111 International travel has been widely associated with ESBL colonization (33). The proportion of 112 ESBL-positive participants that lived internationally in the last 5 years is higher than the ESBL-negative 113 participants (17% vs. 7%); however, it was not significantly associated with ESBL-carriage (fdr-corrected 114 p-value 0.09). Only 8 participants (all ESBL-negative) reported international travel in the previous 30 115 days prior to sample collection.

116 Table 1: Selected demographic characteristics, risk factors, and presence of ESBL-E among all adult

117 participants. The demographic data presented on Table 1 are based on the questionnaire responses from

118 the first visit of all adult participants. The child demographics were not included in the tables or

119 statistical analyses of risk factors, as they were not considered independent of the parent participants.

120 Characteristics of ESBL-E isolates

121 Genome assemblies and phylogenetic relationships

122 All confirmed ESBL-E were identified as Escherichia coli by MALDI-TOF. High-quality draft 123 genome sequences were obtained for the ESBL-E isolates of each 25 initial and 14 second visit samples 124 (Table S3). Genome sizes ranged from 4,981,979 bp to 5,465,567 bp.

125 Isolates belonged to phylogroups B2 (17 isolates), D (4), A (2) B1 (2) and F (1). Of the B2 isolates, 126 12 belonged to the uropathogenic group ST131, including members with *fimH*41 and *fimH*30 alleles (Fig.

127 S2). Other closely related groups, ST2279 (2 isolates), ST1193 (2) and ST636 (1) were also present (Fig.

128 1F). All the samples from second visits that yielded confirmed ESBL-E positive were near-clonal (3-55

129

SNPs) with the isolate of the initial visit from that participant with the sole exception of the isolates from

130 participant 497 (Fig. 1E). The initial isolate from participant 497 was assigned to ST154 in phylogroup 131

B1, whereas the isolate from this participant's second sample, 497R, was assigned to ST106 in 132 phylogroup D (Fig. 1A-F). The parent-child dyad samples were both assigned to phylogroup A but had

133 different sequence types: ST10 (parent) and ST305 (child) and 22,309 SNP differences.

134 Figure 1: Characteristics and classification of ESBL-E isolates. A) Core-genome single nucleotide 135 polymorphisms (SNPs) phylogenetic tree of ESBL-E isolates per participant colored by Clermont

136 phylogroup, highlighting ST131 isolates. B) Phenotypic characterization of antibiotic resistance by isolate 137 tested in Sensititre, after the confirmation as ESBL-E given their resistance to beta-lactams: Cefotaxime 138 and Ceftazidime. C) Antimicrobial resistance genes found by AMRFinderPlus in the genome, transposons 139 (T) or plasmids (1) of each isolate classified by antimicrobial class. D) Beta-lactamase genes found in 140 each isolate, chromosomally or in mobile elements. Circles labelled with a number match plasmids 141 described in Table S5 for each isolate. E) SNPs between first and second sample confirmed as ESBL-142 positive to determine clonality of isolates. F) Sequence type (ST) classification of each isolate, colored by phylogroup. Second samples collected (R) are not included in the figure as they were the same sequence 143 144 type (ST) and share almost the same genetic content as their original sample, with the exception of 497R.

145

#### 146 Antibiotic resistance profile

147 All confirmed ESBL-E positive isolates were phenotypically resistant to Ampicillin, Cefotaxime, 148 Ceftazidime, Cefpodoxime, Ceftriaxone, Cefazolin, and Cephalothin. They presented variable resistance 149 to Cefoxitin and Cefepime as shown in Figure 1B. Of the 25 initial ESBL-E isolates, 18 had resistance to 150 Ciprofloxacin (72%) and 6 were resistant to Gentamicin (24%). ESBL-E isolates from the second visit 151 exhibited the same phenotypic antibiotic resistance profile as their original sample except for 491R, 152 which showed a decreased resistance to Cefoxitin compared to the isolate 491. Some second-visit isolates 153 (C483R and 487R) had resistance to Cefoxitin but were susceptible to other beta-lactams tested and were 154 not confirmed as ESBL-E. None of the isolates were resistant to the carbapenems tested.

All isolates, except for the child sample, carried at least one  $bla_{CTX-M}$  beta lactamase gene (Fig. 1D). The most predominant beta lactamase gene was  $bla_{CTX-M-15}$  in 12 isolates, followed by  $bla_{CTX-M-27}$  in 8 isolates,  $bla_{CTX-M-14}$  in 3 isolates, and  $bla_{CTX-M-1}$  in 2 isolates.  $bla_{CTX-M-15}$  was located on a plasmid in 2 isolates and located within a chromosomally encoded transposon in 2 isolates.  $bla_{CTX-M-15}$  was chromosomally encoded without an obvious mobile genetic element in the remaining 8 isolates (Fig. 1D). All isolates with  $bla_{CTX-M-27}$  carried the gene in IncF plasmids (Table 2).

161 Other beta lactamase genes identified in ESBL-E isolates included *blaEC*, *bla<sub>TEM-1</sub>*, and *bla<sub>OXA-1</sub>*. 162 All ESBL isolates carried the *blaEC* gene that confers resistance to Ampicillin, except for isolates 504 163 and 486, which carried *blaEC5* (not shown). Beta lactamase genes found in lower prevalence were *bla<sub>TEM</sub>*. 164 (carried by 8 isolates) and *bla<sub>OXA-1</sub>* (carried by 6 isolates). Seven copies of *bla<sub>TEM-1</sub>* were carried by IncF 165 plasmids, and one isolate had a copy in the chromosome. bla<sub>OXA-1</sub> was encoded in an IncF plasmid of one 166 isolate, in transposons of two isolates and chromosomally in three isolates (Fig. 1D). Isolate 492 carried 167 three copies of  $bla_{TEM,l}$ , two of them in two different plasmids and one chromosomally. No currently 168 characterized ESBL beta lactamase genes were identified in the child sample, C483. It is not currently

169 clear whether this isolate carries an uncharacterized gene or may have lost its ESBL gene following initial170 isolation on selective media.

171 In addition to these beta lactamases, all isolates carried antimicrobial resistance genes in the 172 efflux class, while 16 carried AR genes for Fosfomycin, 12 for sulfonamides, 12 for tetracycline, 10 for 173 trimethoprim, 7 for macrolides, 8 for quaternary ammonium and 5 for phenicol (Fig. 1C). Interestingly, 174 the child isolate C483 carried two operons (*pco* and *sil*) for resistance genes in metal classes like Copper 175 and Silver, both in close association with transposase genes. Nearly all isolates (22 of 26, including 497R) 176 carried quinolone resistance genes. All ST131 isolates had mutations on gyrA and parE genes and exhibit 177 Ciprofloxacin resistant phenotype, except isolate 482 (Fig. S2). For participants with a confirmed ESBL-178 E isolate from their second visit, all but two encoded the same resistance genes on re-isolation. One of 179 these is 497R, which as discussed elsewhere, denoted a different sequence type from the initial visit 180 isolate. The other, 493R, was identified as clonal (14 SNPs) but lacked erythromycin, trimethoprim, 181 streptomycin, tetracycline, and sulfamethoxazole antibiotic resistance genes that were present in the 182 original isolate, 493. Both isolates carried a near-identical IncF plasmid, but in 493 this plasmid contained 183 an IS6 insertion element that encoded the resistance genes and is missing in the plasmid carried by 493R 184 (possibly lost in a deletion event) (Fig. S3).

185 Virulence genes and Plasmids

Figure 2: Selected virulence genes associated with pathogenic *E. coli* pathotypes. Virulence genes were identified by VirulenceFinder using the genome assemblies of each isolate. Only selected virulence genes are shown based on their associated pathotype. Colored boxes represent the genes associated with each pathotype and gray circles indicate the presence of that gene in each isolate. Isolates are clustered by Clermont phylogroups matching Figure 1. Circles labelled with a number match plasmids described in Table S5 for each isolate.

Phylogroup B2 isolates carried a large variety of virulence genes associated with extraintestinal *E*.
 *coli* (ExPEC) and had three or more genes associated with sepsis-associated *E. coli* (SEPEC) (Fig. 2).

194 However, virulence genes were not limited to phylogroup B2 isolates. The afa genes, encoding for 195 afimbrial adhesins, are also associated with diffusely adherent E. coli (DAEC) and were found in isolates 196 498 and 499 from phylogroup D and 492 from phylogroup B2. Six of 9 genes in the adhesin associated 197 locus (aal) that encodes for the Coli surface antigen 23 (CS23) were present in isolate 498, which also 198 carried the *eatA* gene, encoding for ETEC autotransporter A. Isolate 495 carried the epsilon subtype of 199 intimin outer membrane protein gene, eae, associated with enteropathogenic E. coli (EPEC), hemorrhagic 200 E. coli (EHEC) and Shiga-toxin E. coli (STEC). Isolate 488 has 3 P fimbriae genes (A, C, F) in the same 201 transposon as *bla<sub>0XA-1</sub>* in addition to other resistance genes (*aac(6')-Ib-cr5, ermD, mdtM*).

The most frequently identified and biologically significant plasmids identified belonged to the IncF group, with 24 of the 26 unique ESBL-E isolates carrying at least one plasmid in this group. Most beta lactamases genes located within plasmids were carried by IncF plasmids, except for isolates 497 and 497R which carried  $bla_{CTX-M-1}$  in an IncI1 plasmid (Table 2). The only plasmid carrying more than one beta-lactamase gene was the IncF in isolate 495, which carried genes  $bla_{TEM-1}$ ,  $bla_{CTX-M-15}$ , and  $bla_{OXA-1}$ . Isolate 492 has 2 plasmids each carrying a copy of  $bla_{TEM-1}$ .

- Eight isolates carried IncF plasmids that encoded  $bla_{CTX-M-27}$ , all of which also carried the plasmidencoded enterotoxin, *senB.*  $bla_{CTX-M-27}$  was encoded in an IS6 transposon array frequently associated with up to 16 additional antibiotic resistance genes (Fig. S4). Two of these isolates, 486 and 504, were nearclonal (52 SNPs) and carried plasmids that were 99.98% identical, with the main difference being two 65Kb IS6 transposon arrays encoding (among other genes) 16 resistance genes that are present in the plasmid carried by isolate 504 but absent in 486 (Fig. S5).
- Three isolates carried an IncI1 plasmid, including 497 and 497R. Isolates 497 and 497R, from the same participant at different times and in different sequence groups, shared a near-identical (99.7% pairwise identity) plasmid encoding  $bla_{CTX-M-1}$  (Fig. S6). Plasmid group IncY was identified in 2 isolates, while replicons for IncI2, IncH, IncB/O/K/Z and IncN were each present in one isolate accompanied by an IncF plasmid (Table 2).
- Table 2: Assembled plasmids carried by each isolate identified by PlasmidFinder with encoded antibiotic genes identified by AMRFinderPlus and encoded virulence genes identified by VirulenceFinder. Plasmid number in each isolate matches the numbers in panels C and D of Figure 1 and Figure 2.
- 223 <u>Carriage of antibiotic resistant E. coli among ESBL-E positive participants</u>

224 We also examined the overall prevalence of AR among commensal E. coli in ESBL-E positive 225 participants. Up to 48 E. coli isolates were tested for resistance to ampicillin, ceftriaxone, ciprofloxacin, 226 tetracycline, and trimethoprim. Participants 500 and 498 yielded no E. coli colonies on this medium. Six 227 of 25 ESBL-E positive participants showed dominance of beta-lactam resistant strains in their commensal 228 E. coli community, with more than 50% of the colonies resistant to both ceftriaxone and ampicillin (Fig. 229 3). Five participants carried commensal E. coli resistant to ciprofloxacin. High levels (>50% colonies) of 230 tetracycline resistance were found in 10 of the 25 ESBL-E positive participants. Trimethoprim resistance 231 was less common, with only six participants showing high resistance (>50% colonies) (Fig. 3). In the 232 second samples provided, eight participants had an increase in the proportion of E. coli colonies resistant 233 to both ceftriaxone and ampicillin. Most of the second samples that were ESBL-E negative, had a 234 decreased proportion of commensal *E. coli* colonies that were resistant to the antibiotics tested.

# 235 Figure 3: Antibiotic resistance phenotype of commensal E. coli isolated from ESBL-E positive

236 participants. A range between 1-48 E. coli colonies isolated from ESBL-E positive participants were

237 patched into Mueller Hinton II agar with antibiotics at CSLI standard levels. Each circle size and color

- intensity show the proportion of those colonies that were resistant to the antibiotic tested.
- 239 Gut microbial community composition in ESBL-E positive and ESBL-E negative participants

ESBL-E colonization was not associated with significantly different stool microbiome alpha diversity (Fig. S7). Stool microbiome composition as evaluated by weighted Bray-Curtis distances (Fig. 4A) resulted in a significant PERMANOVA p-value of 0.03. However, the R<sup>2</sup> value was 0.003, indicating that ESBL-E carriage explained only a very small proportion of community variance. Participants with negative second visit samples did not exhibit significantly larger between-sample shifts in stool microbiome composition than participants with continued colonization at re-sampling (Fig. 4B; Fig. S8).

Figure 4: Microbial community similarities based on ESBL-E carriage. A) Bray-Curtis distances of
metagenomic microbiome samples from all participants, organized in a non-metric multidimensional
scaling (NMDS). Magenta dots represent participants that were ESBL-E negative while blue dots
represent participants colonized with ESBL-E. B) Comparison of samples (first, duplicate of first, second
and duplicate of the second sample) from the same ESBL-E positive participant, calculated by BrayCurtis distances. Each number indicates the participant ID, while circles or triangles represent the ESBLE status by sample.

The relative abundance of most microbial classes was similar between ESBL-E positive and ESBL-E negative samples (Fig. S9). However, DESeq2 analysis identified 21 amplicon sequence variants (ASVs) that were significantly enriched and 50 that were significantly depleted in samples from ESBL-E positive vs. ESBL-E negative participants (Fig. 5).

Figure 5: Genus assignments for ASVs identified as enriched or depleted in ESBL-E positive participants. ASVs identified as significantly enriched or depleted by DESeq2 analysis with local fit and Wald test identifying significantly different ASVs under an alpha=0.001. ASVs are colored by phylum and organized by genus. Point size shows normalized mean counts and y axis shows log2fold change in ESBL-E positive participants. ASVs with a positive log2fold change were enriched, while ASVs with a negative log2fold change were depleted in ESBL-E positive participants.

264 Discussion

A key goal of this work was to evaluate asymptomatic carriage of ESBL-E in U.S. residents without significant healthcare exposure. We observed a carriage rate of 4.5% in our study population, which was recruited from the vicinity of the city of Athens, in northeastern Georgia. This reflects a higher prevalence than previous reports from the U.S. that range between 1.7% and 3.5% (26, 30, 32), although this remains

lower than carriage rates reported from European and African countries (34–36). One caveat is that our
study participants were recruited from the southeastern U.S., which has reported a higher rate (19.9%) of
healthcare associated ESBL-E infections than the national average of 12.2% (37).

Our study did not identify any demographic, socioeconomic, environmental, or health-associated risk factors that were significantly associated with the carriage of ESBL-E. This contrasts with previous studies that have reported antibiotic usage (38) and recent international travel (39) as correlated to ESBL-E carriage. These results may have been impacted by the COVID-19 pandemic, which limited international travel during the study period (January 2021-February 2022). This lack of association with specific risk factors suggests that ESBL *E. coli* may be circulating, albeit at low rates, among the general population in the study area.

A large fraction (14 of 22) of ESBL-E positive participants remained positive when re-tested at least 3 months after their initial visit, which is similar to previous reports in Sweden (40). That study, as well as others, found that sequence type ST131 or strains classified in the B2 and D phylogroups were more likely to persist (40, 41). However, our persistent isolates were distributed across many *E. coli* phylotypes, suggesting that persistent colonization is not confined to these phylogroups (42).

Overall, the most prevalent group of ESBL *E. coli* was B2, which matches previous studies in North America (43–46). In terms of sequence types, 46% of the isolates were identified as belonging to ST131, a globally distributed uropathogenic clade that is widely associated with ESBL gene carriage and identified as the most frequent multidrug resistant extraintestinal pathogenic *E. coli* (47). ST131 subclades C1, C2 and C1-M27 (as classified by  $bla_{CTX-M}$  and *fimH* (48)) were all present.

289 All but one isolate carried at least one gene encoding for an CTX-M type enzyme, for a total 290 prevalence of 96%, compared to the 90% reported in a previous review of community isolates from 291 different geographical regions worldwide (49). This suggests that  $bla_{CTX-M}$  carrying E. coli may be a key 292 driver of community ESBL-E spread in the southeastern U.S. In fact, an E. coli carrying bla<sub>CTX-M-15</sub> has 293 been isolated from a stream sample in Athens, GA (50). Among the isolates that carried *bla*<sub>CTX-M</sub> genes, 294 *bla<sub>CTX-M-15</sub>* was the most predominant, followed by *bla<sub>CTX-M-27</sub>* and *bla<sub>CTX-M-14</sub>*. This agrees with previous 295 reports that *bla*<sub>CTX-M-15</sub> is the most abundant beta lactamase gene circulating in the U.S., closely followed 296 by *bla*<sub>CTX-M-27</sub> (51, 52), although a third study of urinary tract infections from gram-negative pathogens 297 isolated in hospitals of Canada and the U.S. (2010-2014) reported bla<sub>CTX-M-14</sub> as more abundant than 298 bla<sub>CTX-M-27</sub> (53). bla<sub>CTX-M-27</sub> was primarily associated with ST131 C1-M27 and C1/H30R clades as 299 previously reported (54) but was also present in ST131 clones with *fimH41*. In all recovered isolates with 300 this gene, the  $bla_{CTX-M-27}$  was borne on an IncF-type plasmid.

In addition to the resistance shown to beta-lactams antibiotics, 72% of the ESBL-E isolates showed
 resistance to Ciprofloxacin and 24% were resistant to Gentamicin. Ciprofloxacin resistance is widely

303 associated with ST131 (17); however, 7 isolates from other groups also exhibited ciprofloxacin resistance 304 suggesting a broader relationship. A previous study of extra-intestinal pathogenic ESBLs from 305 hospitalized patients in India reported a slightly lower prevalence of 65% (55). It remains unclear whether 306 this increased prevalence is because ciprofloxacin resistance is more common in gut isolates or whether 307 this is due to the population studied.

308 The most abundant plasmid type found in our isolates was IncF, which also was the plasmid type 309 carrying the most antibiotic resistance and virulence genes, as has been widely reported (56). While 310 plasmids from the incompatibility group IncI1 are typically associated with transfer of beta lactamase 311 genes (57), we only isolated ESBL-carrying Incl1 plasmids from two participants. The Incl1 plasmid 312 from participant 497, is of particular interest because the ESBL-E. coli isolates obtained from the first and 313 second fecal samples provided by this participant carried a near-identical copies of this plasmid but 314 belonged to two different lineages of E. coli. This suggests a recent transfer of this plasmid in the human 315 gut. Similar events have been reported elsewhere (58–61) and have been used to argue for the potential 316 role of the human gut as a key site of horizontal gene transfer of antibiotic resistance genes.

317 In agreement with previous studies (62), many of our isolates, particularly those belonging to the B2 318 phylogroup, carried virulence genes associated with extra-intestinal pathogenic E. coli including 319 uropathogenic (UPEC) and sepsis associated (SEPEC) strains. The *fimH* gene was the most prevalent 320 virulence factor, followed by UPEC-associated genes chuA, fyuA, usp, and yfcV and kpsMII (found in 321 84% of ESBL-E isolates). Other virulence genes frequently found in our study include *iutA*, *papA*, *papC*. 322 sat, vat, cnfl and hlyA, as previously shown by Iseppi et. al (63), however in contrast to their results sfa 323 was not found in any isolate and *afa* genes were only in 3 isolates. Remarkably, the *eae* gene, previously 324 used to classify EPEC isolates (64), was found in the isolate from participant 495, who also carried the 325 only plasmid in this study with 3 different beta-lactamase genes. The presence of virulence genes in 326 plasmids could explain the hybrid classification into different pathotypes of E. coli and contribute to the 327 evolution of these pathotypes by accumulating virulence factors within the commensal community (65– 328 67).

329 We also examined the frequency of antibiotic resistance among the overall population of commensal 330 *E. coli* present in stool samples from ESBL-E positive participants. More than half of ESBL-E positive 331 participants carried ampicillin- (64%) and tetracycline- (56%) resistant E. coli. However, presumptive 332 ESBL-E made up most commensal E. coli in initial samples from only 6 of 25 ESBL-positive 333 participants. This agrees with previous studies that in most cases the ESBL-producing E. coli is not the 334 dominant strain among gut E. coli (36). Interestingly, 8 of the 22 second samples showed an increase in 335 the fraction of presumptive ESBL-E. coli isolated which could indicate a highly dynamic population 336 structure and/or possible genetic exchange of antibiotic resistance genes among commensal E. coli.

337 Alpha and beta diversity analysis suggests that ESBL-E carriage was not associated with substantially 338 different gut microbiome composition or diversity, consistent with the results of other studies (68, 69). 339 However, pairwise analysis identified multiple taxa with significantly different abundance in carriers and 340 non-carriers. Similar to other studies, we observed enriched taxa belonging to Prevotella (69, 70) and 341 depletion of taxa belonging to Sellimonas (71) and Bacteroides uniformis (72). On the other hand, some 342 taxa that other groups found enriched in ESBL-E carriers were identified as depleted in our ESBL-E 343 communities, including Clostridiales (69), Erysipelotrichaceae, Lactococcus, Bilophila and 344 Negativibacillus (70). In addition, Desulfovibrio and Oscillospira genera were identified as enriched 345 among ESBL-E carriers in our study but depleted in another (68). These differences could be explained 346 by the species of ESBL-Enterobacteriaceae in each study, given that the microbial population differs 347 based on the ESBL-E species (71), or other factors influencing the microbiome composition as discussed 348 before (73).

Notable limitations of our study include that it was restricted to a specific geographic range (Athens, GA and vicinity) and that the study commenced during the global COVID-19 pandemic, which caused multiple large-scale changes in behavior including limitations on international travel. In addition, there was a possible bias provided by the participant self-reporting of risk factors. However, overall our results suggest that a subset of southeast U.S. residents are likely asymptomatic carriers of ESBL-*E. coli*.

#### 354 Conclusions

355 To our knowledge this is the first genomic analysis of community associated ESBL-E carriage in the 356 southeastern U.S. including long-term colonization, as previous studies only focused on the prevalence of 357 ESBL-E or on healthcare-associated isolates. If the results from this study can be extrapolated, it suggests 358 the potential for a small but notable increase in ESBL-E carriage in the U.S. since 2015, consistent with 359 reports that the frequency of community-acquired ESBL-E infections also increased over this period (25) 360 and supporting the role community-associated isolates in the incidence of ESBL-E outbreaks. Long term 361 (>3 months) colonization was common in the study population, which underscores the potential of the 362 human gut microbiome to serve as a long-term reservoir of ESBL Enterobacteriaceae. Colonizing ESBL 363 Enterobacteriaceae were all identified as E. coli including strains that are unlikely to be pathogenic and 364 strains carrying virulence genes associated with extraintestinal pathogenic E. coli. Finally, many strains 365 carried multidrug resistance plasmids and we observed at least one participant where the same plasmid 366 was observed in isolates with different phylogenetic backgrounds, consistent with a role for the human 367 gut as a hotspot for antibiotic resistance gene exchange (74). Overall, our study suggests that the human 368 gut may represent an important but under-recognized reservoir of ESBL genes and ESBL-carrying E. coli 369 and highlights the relevance and importance of understanding the role of gut commensals in mediating 370 the spread of antibiotic resistance.

### 371 Materials and Methods

#### 372 Specimen collection, metadata collection and analysis

373 Recruitment and consenting of participants were performed by the Clinical and Translational 374 Research Unit (CTRU) at the University of Georgia. Inclusion criteria included: the ability and 375 willingness to answer an online survey regarding risk factors and to physically visit the CTRU to obtain 376 and return the specimen collection kit, as well as age >18 years for adult participants. Adult participants 377 with a child age  $\leq$  5 years in their household were invited to enroll the child in the study. Exclusion 378 criteria included pregnancy and in-patient (overnight) hospitalization/health care in the last 12 months for 379 reasons other than uncomplicated childbirth. Prospective participants who reported systemic (oral or 380 intravenous) antibiotic use within the last 48 hours were asked to schedule specimen collection/drop-off 381 for a later date, as were participants with active COVID-19 infections. Children who did not reside with 382 participant parent for 5 days or more per week were also excluded. A signed consent was obtained from 383 each participant or parent. To protect the confidentiality of personal data, all participants were assigned a 384 unique, randomly generated identification number. All research activities involving human subject 385 research were reviewed and approved by the Institutional Review Board (IRB) at University of Georgia, 386 Athens.

387 Participants were provided a stool specimen container that was pre-labeled with their participant 388 ID (Medline Industries, Cat. No. DYND36500) with a scheduled sample return date. Participants were 389 asked to collect a stool sample using the provided collection kit and to complete an online questionnaire 390 to collect demographic information as well as possible environmental risk factors for carriage of antibiotic 391 resistant bacteria (see supplemental materials) as close in time as possible and no more than 12 hours 392 before their scheduled return appointment. After collection, they were instructed to keep the stool 393 specimen in a refrigerator or protected from heat until return to the facility. Upon return to the CTRU, 394 stool specimens were stored at 4°C until processing. Upon transfer to the study team, stool specimens 395 were subdivided for processing, typically within 1-3 hours of receipt (max. 24 hours). For culture work, 396 200 mg of stool specimens were diluted in 1 mL of 1X PBS and immediately processed as described 397 below. For DNA extraction and molecular analyses, 200 mg sub-specimens were transferred to sterile 398 cryovials and stored at -20°C until processing as described below.

Participant data was collected by online survey (Qualtrics) and matched to laboratory samples via alphanumeric participant IDs. Participant surveys consisted of a series of questions relating to each participant's demographics, lifestyle, socioeconomic status, environmental exposures, preexisting medical conditions, and travel experience. All child surveys were completed by a designated parent or guardian. Upon completion of sample collection, all data were downloaded, matched to laboratory results, and cleaned for analysis using R statistical analysis software with 'tidyverse', 'readxl', 'magrittr', 'reshape2'

and 'rcompanion'. ESBL carriage frequencies and Fisher's test with Monte-Carlo simulations were used
to calculate p-values using 'fisher.test' function in R. P-adjusted values were calculated using the
'p.adjust' function with the Benjamini-Hochberg procedure for False Discovery Rate (FDR) (75, 76).

- 408 Statistical significance was considered from p-values less than 0.05.
- 409 Isolation, testing and confirmation of ESBL-E

410 200 mg of each stool specimen was diluted in 1 ml of 1X PBS. 100µl of the diluted aliquot was 411 pre-enriched overnight in 5 ml tryptic soy broth (TSB) at 37°C. 10 µl of the enriched culture was then 412 spread onto CHROMagar<sup>TM</sup> ESBL plates and incubated at 37°C overnight. Well-isolated colonies from 413 CHROMagar ESBL plates were re-streaked for isolation and purification on the same medium and 414 incubated under the same conditions. Presumptive ESBL-producing colonies were re-streaked on blood 415 agar, identified by MALDI-TOF MS, and confirmed by antibiotic resistant profiling using Sensititre panel 416 ESB1F at the UGA Veterinary Diagnostics Laboratory. An isolate was considered ESBL-positive if it 417 was resistant to Cefotaxime and Ceftazidime but susceptible when clavulanic acid was added to each. 418 Other antibiotics tested with Sensititre included Ampicillin, Cefazolin, Cefepime, Cefoxitin, 419 Cefpodoxime, Ceftriaxone, Cephalothin, Ciprofloxacin, Gentamicin, Imipenem, Meropenem and 420 Piperacillin/Tazobactam. Confirmed ESBL-positive participants were requested to provide a second 421 sample at least 90 days after the initial participation. 22 of 25 positive participants provided a second 422 sample, the remaining 3 could not be contacted after multiple attempts. Second-visit samples were 423 processed under the same conditions as the first samples.

### 424 <u>Whole-genome sequencing and analysis</u>

Isolated colonies from ESBL-confirmed participants were used for whole-genome analysis. Genomic DNA of isolates was extracted using Omega Biotek Bacterial DNA Kit. Purified DNA was arrayed in 96-well plates, normalized, and run on agarose minigels for QC. Genomic libraries were created using an NEBNext Ultra II FS DNA Library Prep Kit with custom primers and protocols (77) and an Opentrons OT-2 robot. Libraries for all ESBL-confirmed isolates were sequenced on a NovaSeq S4 6000 to obtain PE150 reads. Trimming and quality filtering was performed via Trimmomatic v0.39.

For long-read sequencing, DNA extracts were normalized to 50 ng per 9 μl. Oxford Nanopore
Technologies (ONT) libraries were prepared following manufacturer's instructions for the rapid barcode
96 kit and cleaned with Ampure XP beads. A total of 75 μl of library was loaded onto an ONT MinION
flow cell (9.3.1) for sequencing. Following sequencing, bases were called using super accuracy mode
with Guppy v6.1.1.

*De novo* assembly was performed using Unicycler v0.4.7. using the short-reads first approach and
default settings (78). A phylogenetic tree between ESBL-E genomes was constructed using maximum
likelihood and core single nucleotide polymorphisms with Parsnp, with a randomly selected reference

439 genome (AREA 490). Core genome single nucleotide polymorphisms (SNPs) between isolates from first 440 and second samples were calculated using CSI Phylogeny (79, 80). AMRFinder v3.9.8 was used to 441 identify antimicrobial resistance genes in assembled genomes using the Plus genes database (--plus) and 442 E. coli as the reference organism (-O) to identify point mutations (81). Mobile genetic elements were 443 identified using MobileElementFinder v1.0.3 with antimicrobial resistance genes annotated (82). Tools 444 from the Center for Genomic Epidemiology (http://www.genomicepidemiology.org/services/) that were 445 used to analyze the hybrid assemblies including: MLST v2.0.9 with configuration for Escherichia coli #1 446 and a minimum depth of 5X; SeroTypeFinder v2.0.1 with 85% threshold ID and 60% minimum length, 447 FimTyper v1.0 with 95% threshold ID, 95% threshold identity and 60% minimum coverage and 448 VirulenceFinder v2.0.3 for *E. coli* with 90% threshold ID and 60% minimum length (83–86). Assemblies 449 were classified by phylogroups using the ClermonTyping web server (http://clermontyping.iame-450 research.center)(87).

### 451 <u>Microbial community characterization</u>

Fecal *E. coli* were isolated without antibiotic selection from all stool samples using CHROMagar ECC. Up to 48 well-isolated colonies (if available) were re-streaked on LB plates for purity, then arrayed in 96-well plates to grow overnight with Mueller Hinton II broth media. 3  $\mu$ l subsamples of the overnight culture were patched in Mueller Hinton II agar plates containing antibiotics at CLSI standards: Ampicillin (32  $\mu$ g/ml), Ceftriaxone (32  $\mu$ g/ml), Ciprofloxacin (4  $\mu$ g/ml), Tetracycline (4  $\mu$ g/ml) and Trimethoprim (8  $\mu$ g/ml) to characterize the AR profile of the commensal *E. coli* community in the ESBL-E positive participants.

459 For 16S rRNA gene library sequencing, DNA was isolated from 200 mg of each stool sample 460 with the Omega Biotek Stool DNA kit following the manufacturer protocol for pathogen detection 461 (Omega Biotek, Norcross, GA, USA). The optional incubation with DS buffer and Proteinase K was 462 performed to improve recovery of Gram-positive bacteria. Extracted DNA was eluted in 100µl of elution 463 buffer from the kit heated at 65°C. DNA concentrations were measured with NanoDrop. Amplification of 464 16S rRNA gene was done using primers 515F and 806R as described previously (88), followed by library 465 sequencing with Illumina MiSeq 250 x 250 bp at the Georgia Genomics Facility. Sequence analysis was 466 performed using DADA2 (version 1.18) in R (version 4.0.2) including filtering, trimming, merge and 467 taxonomy assignment with SILVA database, version 138 (89, 90). Data analyses were done in R using 468 phyloseq, vegan, dplyr, tidyverse and DESeq packages with samples rarefied to a depth of 10,000 when 469 needed (91, 92).

470 Data availability

Whole-genome assemblies and 16S rDNA sequences have been submitted to NCBI under the BioProject:PRJNA894544.

#### 473

#### 474 Acknowledgements

This work was supported by BAA contract no. 75D30120C09496 from the Centers for Disease Control and Prevention. Funders had no role in data collection and interpretation, or the decision to submit the publication. Participants recruitment and sample processing was performed with the help of the CTRU at University of Georgia, which is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number: UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes

- defined the defined of Health.
- 482 Author roles based on CRediT taxonomy: Coralis Rodriguez Garcia, data curation, formal analysis,
- 483 investigation, methodology, visualization, writing original draft; William A. Norfolk, data curation,
- 484 formal analysis, visualization; Amanda K. Howard, investigation, methodology, formal analysis; Amanda
- 485 L. Glatter, investigation; Megan S. Beaudry, investigation; Nicholas A. Mallis, investigation; Michael
- 486 Welton, conceptualization, methodology; Travis C. Glenn, conceptualization, methodology, supervision,
- 487 project administration; Erin K. Lipp, conceptualization, methodology, supervision, project administration;
- 488 Elizabeth A. Ottesen, conceptualization, funding acquisition, methodology, supervision, project
- 489 administration, writing review and editing.
- 490

494

We also thank Andreas Handel, Jonathan Frye, and Charlene Jackson for their advice regardingmethodology and data analysis, as well as Marissa Howard, Kelly Petersen, Bryce Miller, Katie Dillon,

493 Kirty Muthyala, Claire Pearson for their assistance in data collection.

## 495 **References**

- 496 1. WHO Association Media Centre. 2015. Sixty-Eighth World Health Assembly. World Health Organization.
- 497 2. CDC. 2019. Antibiotic Resistance Threats in The United States, 2019 U.S. Department of Health and Human Services.
- 499 3. Nelson RE, Slayton RB, Stevens VW, Jones MM, Khader K, Rubin MA, Jernigan JA, Samore MH. 2017.
  500 Attributable mortality of healthcare-associated infections due to multidrug-resistant gram-negative bacteria and methicillin-resistant *Staphylococcus aureus*. Infect Control Hosp Epidemiol 38:848–856.
- Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, Larson EL. 2012. Costs of healthcare-and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clinical Infectious Diseases 55:807–815.
- 5. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. Infection 11:315–317.
- Bush K, Bradford PA. 2020. Epidemiology of B-Lactamase-Producing Pathogens. Clin Microbiol Rev 33:1–37.
- 510 7. Rupp ME, Fey PD. 2003. Extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*: considerations for diagnosis, prevention and drug treatment. Drugs 63:353–365.
- 512 8. Whichard JM, Joyce K, Fey PD, Nelson JM, Angulo FJ, Barrett TJ. 2005. β-Lactam Resistance and *Enterobacteriaceae*, United States. Emerg Infect Dis 11:1464–1466.
- 514 9. Rawat D, Nair D. 2010. Extended-spectrum β-lactamases in gram negative bacteria. J Glob Infect Dis 2:263.


- 515 10. Castanheira M, Simner PJ, Bradford PA. 2021. Extended-spectrum β-lactamases: An update on their characteristics, epidemiology and detection. JAC Antimicrob Resist 3.
- 51711.Doi Y, Iovleva A, Bonomo RA. 2017. The ecology of extended-spectrum β-lactamases (ESBLs) in the<br/>developed world. J Travel Med 24:S44–S51.
- Logan LK, Rispens JR, Medernach RL, Domitrovic TN, Hujer AM, Marshall SH, Rudin SD, Qureshi NK,
  Zheng X, Hayden MK, Weinstein RA, Bonomo RA. 2021. A Multicentered Study of the Clinical and
  Molecular Epidemiology of TEM- and SHV-type Extended-Spectrum Beta-Lactamase Producing *Enterobacterales* Infections in Children. Pediatric Infectious Disease Journal 40:39–43.
- 523 13. Cantón R, González-Alba JM, Galán JC. 2012. CTX-M enzymes: Origin and diffusion. Front Microbiol 3.
- **524** 14. Cantón R, Coque TM. 2006. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9:466–475.
- Logan LK, Hujer AM, Marshall SH, Domitrovic TN, Rudin SD, Zheng X, Qureshi NK, Hayden MK,
  Scaggs FA, Karadkhele A, Bonomo RA. 2016. Analysis of β-Lactamase Resistance Determinants in
  Enterobacteriaceae from Chicago Children: a Multicenter Survey. Antimicrob Agents Chemother 60:3462–
  3469.
- 529 16. Hu F, O'Hara JA, Rivera JI, Doi Y. 2014. Molecular Features of Community-Associated Extended 530 Spectrum-β-Lactamase-Producing Escherichia coli Strains in the United States. Antimicrob Agents
   531 Chemother 58:6953–6957.
- 532 17. Matsumura Y, Pitout JDD, Peirano G, Devinney R, Noguchi T, Yamamoto M, Gomi R, Matsuda T, Nakano
  533 S, Nagao M, Tanaka M, Ichiyama S. 2017. Rapid Identification of Different Escherichia coli Sequence Type
  534 131 Clades. Antimicrob Agents Chemother 61:1–9.
- 535 18. Salamzade R, McElheny CL, Manson AL, Earl AM, Shaikh N, Doi Y. 2023. Genomic epidemiology and antibiotic susceptibility profiling of uropathogenic *Escherichia coli* among children in the United States.
  537 mSphere 8.
- 538 19. Nicolas-Chanoine MH, Bertrand X, Madec JY. 2014. Escherichia coli st131, an intriguing clonal group.
  539 Clin Microbiol Rev 27:543–574.
- 540 20. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. 2015. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Saudi J Biol Sci 22:90–101.
- 542 21. Johnson TJ, Wannemuehler YM, Johnson SJ, Logue CM, White DG, Doetkott C, Nolan LK. 2007. Plasmid
  543 replicon typing of commensal and pathogenic Escherichia coli isolates. Appl Environ Microbiol 73:1976–
  544 1983.
- 545 22. Lukac PJ, Bonomo RA, Logan LK. 2015. Extended-Spectrum -Lactamase-Producing Enterobacteriaceae in Children: Old Foe, Emerging Threat. Clinical Infectious Diseases https://doi.org/10.1093/cid/civ020.
- 547 23. Carattoli A. 2011. Plasmids in Gram negatives: Molecular typing of resistance plasmids. International Journal of Medical Microbiology 301:654–658.
- 549 24. van Duin D, Paterson DL. 2020. Multidrug-Resistant Bacteria in the Community: An Update. Infect Dis Clin North Am 34:709–722.
- 551 25. Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, Dessalegn N, Enyew A, Roujeinikova A,
  552 Alamneh E, Mirkazemi C, Peterson GM, Bezabhe WM. 2022. Comparison of the global prevalence and
  553 trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community
  554 settings: A systematic review and meta-Analysis. JAC Antimicrob Resist 4.
- Bezabih YM, Sabiiti W, Alamneh E, Bezabih A, Peterson GM, Bezabhe WM, Roujeinikova A. 2021. The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community. Journal of Antimicrobial Chemotherapy 76:22–29.
- 558 27. Bevan ER, Jones AM, Hawkey PM. 2017. Global epidemiology of CTX-M β-lactamases: Temporal and geographical shifts in genotype. Journal of Antimicrobial Chemotherapy 72.
- Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, Lewis JS, Howard WJ, Johnson LE, Polsky B, Jorgensen JH, Richter SS, Shutt KA, Paterson DL. 2013. Community-associated extended-spectrum -lactamase-producing Escherichia coli infection in the United States. Clinical Infectious Diseases 56:641–648.
- 564 29. Doi Y, Adams J, O'Keefe A, Quereshi Z, Ewan L, Paterson DL. 2007. Community-acquired extended spectrum B-lactamase producers, United States.
- 30. Vento TJ, Cole DW, Mende K, Calvano TP, Rini EA, Tully CC, Zera WC, Guymon CH, Yu X, Cheatle KA,
  Akers KS, Beckius ML, Landrum ML, Murray CK. 2013. Multidrug-resistant gram-negative bacteria
  colonization of healthy US military personnel in the US and Afghanistan. BMC Infect Dis 13.

- 569 31. Weisenberg SA, Mediavilla JR, Chen L, Alexander EL, Rhee KY, Kreiswirth BN, Jenkins SG. 2012.
  570 Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae in International Travelers and Non-Travelers in New York City. PLoS One 7:2010–2013.
- 572 32. Islam S, Selvarangan R, Kanwar N, McHenry R, Chappell JD, Halasa N, Wikswo ME, Payne DC, Azimi
  573 PH, McDonald LC, Gomez-Duarte OG. 2018. Intestinal Carriage of Third-Generation Cephalosporin574 Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Healthy US Children. J
  575 Pediatric Infect Dis Soc 7:234–240.
- 576 33. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. 2016. Fecal Colonization with Extended577 spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors among Healthy Individuals: A
  578 Systematic Review and Metaanalysis. Clinical Infectious Diseases 63:310–318.
- 579 34. Geser N, Stephan R, Korczak BM, Beutin L, Hächler H. 2012. Molecular identification of extended580 spectrum-β-lactamase genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland.
  581 Antimicrob Agents Chemother 56:1609–1612.
- 582 35. Mshana SE, Falgenhauer L, Mirambo MM, Mushi MF, Moremi N, Julius R, Seni J, Imirzalioglu C, Matee
  583 M, Chakraborty T. 2016. Predictors of blaCTX-M-15 in varieties of Escherichia coli genotypes from
  584 humans in community settings in Mwanza, Tanzania. BMC Infect Dis 16:1–9.
- 36. Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S, Bertrand X, Thomas-Jean F, Bert F, Moyat M, Meiller
  E, Marcon E, Danchin N, Noussair L, Moreau R, Leflon-Guibout V. 2013. 10-fold increase (2006-11) in the
  rate of healthy subjects with extended-spectrum β-lactamase-producing Escherichia coli faecal carriage in a
  parisian check-up centre. Journal of Antimicrobial Chemotherapy 68:562–568.
- 589 37. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of β-lactamases
   590 among enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against
   isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58:833–838.
- 38. van den Bunt G, van Pelt W, Hidalgo L, Scharringa J, de Greeff SC, Schürch AC, Mughini-Gras L, Bonten MJM, Fluit AC. 2019. Prevalence, risk factors and genetic characterisation of extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae (ESBL-E and CPE): A community-based cross-sectional study, the Netherlands, 2014 to 2016. Eurosurveillance 24.
- Mizuno Y, Miura Y, Yamaguchi T, Matsumoto T. 2016. Extended-spectrum β-lactamase-producing
   Enterobacteriaceae colonisation in long-term overseas business travellers. Travel Med Infect Dis 14:561–
   567.
- 599 40. Titelman E, Hasan CM, Iversen A, Nauclér P, Kais M, Kalin M, Giske CG. 2014. Faecal carriage of
   600 extended-spectrum β-lactamase-producing Enterobacteriaceae is common 12 months after infection and is
   601 related to strain factors. Clinical Microbiology and Infection 20.
- 41. van Duijkeren E, Wielders CCH, Dierikx CM, van Hoek AHAM, Hengeveld P, Veenman C, Florijn A,
  Lotterman A, Smit LAM, van Dissel JT, Maassen CBM, de Greeff SC. 2018. Long-term Carriage of
  Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in the General
  Population in The Netherlands. Clin Infect Dis 66.
- 42. Rumball NA, Alm EW, McLellan SL. 2023. Genetic Determinants of Escherichia coli Survival in Beach
  Sand. Appl Environ Microbiol 89.
- 43. Logue CM, Doetkott C, Mangiamele P, Wannemuehler YM, Johnson TJ, Tivendale KA, Li G, Sherwood
  43. JS, Nolan LK. 2012. Genotypic and phenotypic traits that distinguish neonatal meningitis-associated
  44. Escherichia coli from fecal E. coli isolates of healthy human hosts. Appl Environ Microbiol 78.
- 44. Johnson JR, Owens K, Gajewski A, Kuskowski MA. 2005. Bacterial characteristics in relation to clinical source of Escherichia coli isolates from women with acute cystitis or pyelonephritis and uninfected women.
  613 J Clin Microbiol 43.
- 614 45. Zhang L, Foxman B, Marrs C. 2002. Both urinary and rectal Escherichia coli isolates are dominated by strains of phylogenetic group B2. J Clin Microbiol 40.
- 616 46. Sannes MR, Kuskowski MA, Owens K, Gajewski A, Johnson JR. 2004. Virulence factor profiles and
  617 phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control
  618 subjects. Journal of Infectious Diseases 190.
- 619 47. Rogers BA, Doi Y. 2013. Who Is Leading This Dance? Understanding the Spread of Escherichia coli
  620 Sequence Type 131. Infect Control Hosp Epidemiol 34.
- 48. Petty NK, Zakour NLB, Stanton-Cook M, Skippington E, Totsika M, Forde BM, Phan MD, Moriel DG,
  Peters KM, Davies M, Rogers BA, Dougan G, Rodriguez-Baño J, Pascual A, Pitout JDD, Upton M,
  Paterson DL, Walsh TR, Schembri MA, Beatson SA. 2014. Global dissemination of a multidrug resistant
  Escherichia coli clone. Proc Natl Acad Sci U S A 111.

625	49.	Woerther PL, Burdet C, Chachaty E, Andremont A. 2013. Trends in human fecal carriage of extended-
626		spectrum β-lactamases in the community: Toward the globalization of CTX-M. Clin Microbiol Rev 26:744-
627		758.
628	50.	Cho S, Nguyen HAT, McDonald JM, Woodley TA, Hiott LM, Barrett JB, Jackson CR, Frye JG. 2019.
629		Genetic characterization of antimicrobial-resistant escherichia coli isolated from a mixed-use watershed in
630		northeast Georgia, USA. Int J Environ Res Public Health 16:1–14.
631	51.	Duffy N, Karlsson M, Reses HE, Campbell D, Daniels J, Stanton RA, Janelle SJ, Schutz K, Bamberg W,
632	51.	Rebolledo PA, Bower C, Blakney R, Jacob JT, Phipps EC, Flores KG, Dumyati G, Kopin H, Tsay R, Kainer
633		MA, Muleta D, Byrd-Warner B, Grass JE, Lutgring JD, Rasheed JK, Elkins CA, Magill SS, See I. 2022.
634		
635		Epidemiology of extended-spectrum $\beta$ -lactamase-producing Enterobacterales in five US sites participating in the Emerginal Infactions Program 2017. Infact Control Hear Enidemial 42:1586–1504
	50	in the Emerging Infections Program, 2017. Infect Control Hosp Epidemiol 43:1586–1594.
636	52.	Mostafa HH, Cameron A, Taffner SM, Wang J, Malek A, Dumyati G, Hardy DJ, Pecora ND. 2020.
637		Genomic Surveillance of Ceftriaxone-Resistant Escherichia coli in Western New York Suggests the
638		Extended-Spectrum $\beta$ -Lactamase blaCTX-M-27 Is Emerging on Distinct Plasmids in ST38. Front Microbiol
639		11.
640	53.	Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF. 2016. Susceptibility patterns and
641		ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART
642		2010–2014. Diagn Microbiol Infect Dis 85:459–465.
643	54.	Matsumura Y, Pitout JDD, Gomi R, Matsuda T, Noguchi T, Yamamoto M, Peirano G, De Vinney R,
644		Bradford PA, Motyl MR, Tanaka M, Nagao M, Takakura S, Ichiyama S. 2016. Global Escherichia coli
645		sequence type 131 clade with blaCTX-M-27 gene. Emerg Infect Dis 22:1900–1907.
646	55.	Chakraborty A, Adhikari P, Shenoy S, Saralaya V. 2015. Clinical significance and phylogenetic background
647		of extended spectrum $\beta$ -lactamase producing Escherichia coli isolates from extra-intestinal infections. J
648		Infect Public Health 8:248–253.
649	56.	Carattoli A. 2009. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother
650		53:2227–2238.
651	57.	Carattoli A, Villa L, Fortini D, García-Fernández A. 2021. Contemporary IncI1 plasmids involved in the
652	57.	transmission and spread of antimicrobial resistance in Enterobacteriaceae. Plasmid
653		https://doi.org/10.1016/j.plasmid.2018.12.001.
654	58.	Göttig S, Gruber TM, Stecher B, Wichelhaus TA, Kempf VAJ. 2015. In vivo horizontal gene transfer of the
655	50.	carbapenemase OXA-48 during a nosocomial outbreak. Clinical Infectious Diseases 60.
656	59.	Trobos M, Lester CH, Olsen JE, Frimodt-Møller N, Hammerum AM. 2009. Natural transfer of
657	59.	sulphonamide and ampicillin resistance between Escherichia coli residing in the human intestine. Journal of
658		Antimicrobial Chemotherapy 63.
659	60	Sandegren L, Linkevicius M, Lytsy B, Melhus Å, Andersson DI. 2012. Transfer of an Escherichia coli
660	60.	
		ST131 multiresistance cassette has created a Klebsiella pneumoniae-specific plasmid associated with a
661	<b>C1</b>	major nosocomial outbreak. Journal of Antimicrobial Chemotherapy 67.
662	61.	Hazen TH, Mettus R, McElheny CL, Bowler SL, Nagaraj S, Doi Y, Rasko DA. 2018. Diversity among
663		blaKPC-containing plasmids in Escherichia coli and other bacterial species isolated from the same patients.
664		Sci Rep 8:10291.
665	62.	Geurtsen J, de Been M, Weerdenburg E, Zomer A, McNally A, Poolman J. 2022. Genomics and pathotypes
666		of the many faces of Escherichia coli. FEMS Microbiol Rev 46.
667	63.	Iseppi R, Di Cerbo A, Messi P, Sabia C. 2020. Antibiotic resistance and virulence traits in vancomycin-
668		resistant enterococci (Vre) and extended-spectrum $\beta$ -lactamase/ampc-producing (ESBL/ampc)
669		enterobacteriaceae from humans and pets. Antibiotics 9.
670	64.	Chandra M, Cheng P, Rondeau G, Porwollik S, McClelland M. 2013. A single step multiplex PCR for
671		identification of six diarrheagenic E. coli pathotypes and Salmonella. International Journal of Medical
672		Microbiology 303:210–216.
673	65.	Hazen TH, Michalski J, Luo Q, Shetty AC, Daugherty SC, Fleckenstein JM, Rasko DA. 2017. Comparative
674		genomics and transcriptomics of Escherichia coli isolates carrying virulence factors of both
675		enteropathogenic and enterotoxigenic E. coli. Sci Rep 7.
676	66.	Yu F, Chen X, Zheng S, Han D, Wang Y, Wang R, Wang B, Chen Y. 2018. Prevalence and genetic
677		diversity of human diarrheagenic Escherichia coli isolates by multilocus sequence typing. International
678		Journal of Infectious Diseases 67:7–13.
679	67.	Neuwirth C, Siebor E, Pechinot A, Duez JM, Pruneaux M, Garel F, Kazmierczak A, Labia R. 2001.
680		Evidence of in vivo transfer of a plasmid encoding the extended-spectrum $\beta$ -lactamase TEM-24 and other


681		resistance factors among different members of the family Enterobacteriaceae. J Clin Microbiol 39:1985–
682 683	68.	1988. Gosalbes MJ, Vázquez-Castellanos JF, Angebault C, Woerther PL, Ruppé E, Ferrús ML, Latorre A,
684	00.	And remont A, Moya A. 2016. Carriage of enterobacteria producing extended-spectrum $\beta$ -lactamases and
685		composition of the gut microbiota in an Amerindian community. Antimicrob Agents Chemother 60:507–
686		514.
687	69.	Le Bastard Q, Chapelet G, Birgand G, Hillmann BM, Javaudin F, Hayatgheib N, Bourigault C, Bemer P, De
688	07.	Decker L, Batard E, Lepelletier D, Montassier E. 2020. Gut microbiome signatures of nursing home
689		residents carrying Enterobacteria producing extended-spectrum $\beta$ -lactamases. Antimicrob Resist Infect
690		Control 9.
691	70.	Peng Y, Liang S, Poonsuk K, On H, Li SW, Pascal Maurin MM, Chan CH, Chan CL, Sin ZY, Tun HM.
692		2021. Role of gut microbiota in travel-related acquisition of extended spectrum $\beta$ -lactamase-producing
693		Enterobacteriaceae. J Travel Med 28:1–11.
694	71.	Prevel R, Enaud R, Orieux A, Camino A, Sioniac P, M'Zali F, Dubois V, Berger P, Boyer A, Delhaes L,
695		Gruson D. 2023. Bridging gut microbiota composition with extended-spectrum beta-lactamase
696		Enterobacteriales faecal carriage in critically ill patients (microbe cohort study). Ann Intensive Care 13.
697	72.	Piewngam P, Quiñones M, Thirakittiwatthana W, Yungyuen T, Otto M, Kiratisin P. 2019. Composition of
698		the intestinal microbiota in extended-spectrum β-lactamase-producing Enterobacteriaceae carriers and non-
699		carriers in Thailand. Int J Antimicrob Agents 53.
700	73.	Stoppe N de C, Silva JS, Carlos C, Sato MIZ, Saraiva AM, Ottoboni LMM, Torres TT. 2017. Worldwide
701		phylogenetic group patterns of Escherichia coli from commensal human and wastewater treatment plant
702		isolates. Front Microbiol 8.
703	74.	Nhu NTQ, Young VB. 2023. The Relationship Between the Microbiome and Antimicrobial Resistance.
704		Clinical Infectious Diseases 77:S479–S486.
705	75.	Benjamini Y, Hochberg Y. 1995. Controlling the False Discovery Rate: A Practical and Powerful Approach
706		to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 57:289-300.
707	76.	Jafari M, Ansari-Pour N. 2019. Why, when and how to adjust your P values? Cell J 20.
708	77.	Glenn TC, Nilsen RA, Kieran TJ, Sanders JG, Bayona-Vásquez NJ, Finger JW, Pierson TW, Bentley KE,
709		Hoffberg SL, Louha S, Garcia-De Leon FJ, Del Rio Portilla MA, Reed KD, Anderson JL, Meece JK,
710		Aggrey SE, Rekaya R, Alabady M, Belanger M, Winker K, Faircloth BC. 2019. Adapterama I: Universal
711		stubs and primers for 384 unique dual-indexed or 147,456 combinatorially-indexed Illumina libraries (iTru
712	70	& iNext). PeerJ 2019.
713 714	78.	Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: Resolving bacterial genome assemblies from
714	70	short and long sequencing reads. PLoS Comput Biol 13:1–22.
716	79.	Treangen TJ, Ondov BD, Koren S, Phillippy AM. 2014. The harvest suite for rapid core-genome alignment
717	80.	and visualization of thousands of intraspecific microbial genomes. Genome Biol 15:1–15. Kaas RS, Leekitcharoenphon P, Aarestrup FM, Lund O. 2014. Solving the problem of comparing whole
718	80.	bacterial genomes across different sequencing platforms. PLoS One 9:1–8.
719	81.	Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, Hoffmann M, Pettengill
720	01.	JB, Prasad AB, Tillman GE, Tyson GH, Klimke W. 2021. AMRFinderPlus and the Reference Gene Catalog
721		facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence.
722		Sci Rep 11.
723	82.	Johansson MHK, Bortolaia V, Tansirichaiya S, Aarestrup FM, Roberts AP, Petersen TN. 2021. Detection of
724		mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly
725		developed web tool: MobileElementFinder. Journal of Antimicrobial Chemotherapy 76:101–109.
726	83.	Larsen M V., Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Pontén T,
727		Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence typing of total-genome-sequenced bacteria.
728		J Clin Microbiol 50:1355–1361.
729	84.	Joensen KG, Tetzschner AMM, Iguchi A, Aarestrup FM, Scheutz F. 2015. Rapid and easy in silico
730		serotyping of Escherichia coli isolates by use of whole-genome sequencing data. J Clin Microbiol 53:2410-
731		2426.
732	85.	Roer L, Tchesnokova V, Allesøe R, Muradova M, Chattopadhyay S, Ahrenfeldt J, Thomsen MCF, Lund O,
733		Hansen F, Hammerum AM, Sokurenko E, Hasmana H. 2017. Development of Web Tool for Escherichia
734	_	coli Subtyping Based on fimH Alleles. J Clin Microbiol 55:2538–2543.
735	86.	Malberg Tetzschner AM, Johnson JR, Johnston BD, Lund O, Scheutzd F. 2020. In Silico Genotyping of
736		Escherichia coli Isolates for Sequencing Data. J Clin Microbiol 58:e01269-20.

- 87. Beghain J, Bridier-Nahmias A, Nagard H Le, Denamur E, Clermont O. 2018. ClermonTyping: An easy-to-use and accurate in silico method for Escherichia genus strain phylotyping. Microb Genom 4:1–8.
- 739 88. Tinker KA, Ottesen EA. 2016. The core gut microbiome of the American cockroach, Periplaneta americana, is stable and resilient to dietary shifts. Appl Environ Microbiol 82:6603–6610.
- 741 89. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13:581–583.
- 90. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. 2013. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res 41:590–596.
- P1. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:1–21.
- 748 92. McMurdie PJ, Holmes S. 2013. Phyloseq: An R Package for Reproducible Interactive Analysis and
  749 Graphics of Microbiome Census Data. PLoS One 8.
  750




751

754 Figure 1: Characteristics and classification of ESBL-E isolates. A) Core-genome single nucleotide 755 polymorphisms (SNPs) phylogenetic tree of ESBL-E isolates per participant colored by Clermont 756 phylogroup, highlighting ST131 isolates. B) Phenotypic characterization of antibiotic resistance by isolate 757 tested in Sensititre, after the confirmation as ESBL-E given their resistance to beta-lactams: Cefotaxime 758 and Ceftazidime. C) Antimicrobial resistance genes found by AMRFinderPlus in the genome, transposons 759 (T) or plasmids (1) of each isolate classified by antimicrobial class. D) Beta-lactamase genes found in 760 each isolate, chromosomally or in mobile elements. Circles labelled with a number match plasmids 761 described in Table S5 for each isolate. E) SNPs between first and second sample confirmed as ESBL-762 positive to determine clonality of isolates. F) Sequence type (ST) classification of each isolate, colored by 763 phylogroup. Second samples collected (R) are not included in the figure as they were the same sequence 764 type (ST) and share almost the same genetic content as their original sample, with the exception of 497R.



765

Figure 2: Selected virulence genes associated with pathogenic *E. coli* pathotypes. Virulence genes were identified by VirulenceFinder using the genome assemblies of each isolate. Only selected virulence genes are shown based on their associated pathotype. Colored boxes represent the genes associated with each pathotype and gray circles indicate the presence of that gene in each isolate. Isolates are clustered by Clermont phylogroups matching Figure 1. Circles labelled with a number match plasmids described in Table S5 for each isolate.



774

775 Figure 3: Antibiotic resistance phenotype of commensal E. coli isolated from ESBL-E positive 776 participants. A range between 1-48 E. coli colonies isolated from ESBL-E positive participants were 777 patched into Mueller Hinton II agar with antibiotics at CSLI standard levels. Each circle size and color 778 intensity show the proportion of those colonies that were resistant to the antibiotic tested.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.03.24302254; this version posted February 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 4: Microbial community similarities based on ESBL-E carriage. A) Bray-Curtis distances of metagenomic microbiome samples from all participants, organized in a non-metric multidimensional scaling (NMDS). Magenta dots represent participants that were ESBL-E negative while blue dots represent participants colonized with ESBL-E. B) Comparison of samples (first, duplicate of first, second and duplicate of the second sample) from the same ESBL-E positive participant, calculated by Bray-Curtis distances. Each number indicates the participant ID, while circles or triangles represent the ESBL-First E status by sample.






Figure 5: Genus assignments for ASVs identified as enriched or depleted in ESBL-E positive participants. ASVs identified as significantly enriched or depleted by DESeq2 analysis with local fit and Wald test identifying significantly different ASVs under an alpha=0.001. ASVs are colored by phylum and organized by genus. Point size shows normalized mean counts and y axis shows log2fold change in ESBL-E positive participants. ASVs with a positive log2fold change were enriched, while ASVs with a negative log2fold change were depleted in ESBL-E positive participants.

## 798 Table 1: Selected demographic characteristics, risk factors, and presence of ESBL-E among all adult

- 799 *participants.* The demographic data presented on Table 1 are based on the questionnaire responses from
- 800 the first visit of all adult participants. The child demographics were not included in the tables or
- 801 statistical analyses of risk factors, as they were not considered independent of the parent participants.

Demographic or Risk Factor	Ν	ESBL-E positive N=24	ESBL-E negative N=481	p-value <sup>1</sup> /FDR p- adjusted <sup>2</sup>	
Biological Sex		1		U U	
Female	349	13 (54%)	336 (70%)	0.46/0.70	
Male	156	11 (46%)	145 (30%)	0.12/0.79	
Race		• • •			
Asian	37	4 (17%)	33 (7%)		
Black or African American	59	5 (21%)	54 (11%)	0.17/0.79	
White	377	15 (63%)	362 (75%)		
Age (years)					
18-29	234	13 (54%)	221 (46%)		
30-39	84	2 (8%)	82 (17%)		
40-49	53	3 (13%)	50 (10%)	]	
50-59	49	2 (8%)	47 (10%)	0.17/.079	
60-69	45	1 (4%)	44 (9%)		
70-79	22	2 (8%)	20 (4%)		
80-89	5	0 (0%)	5 (1%)		
Antibiotic use in the past 1 m	onth (ora	, topical, or intravenou	is)		
Yes	47	2 (8%)	45 (9%)	1 /1	
No	454	22 (92%)	432 (90%)	1/1	
Gastrointestinal conditions of		ns in the past 1 month			
Yes	177	8 (33%)	169 (35%)	1 /1	
No	327	16 (67%)	311 (65%)	1/1	
Urinary tract infection in the	past 1 mo	onth (self-diagnosed or	diagnosed by doctor)		
Yes	13	1 (4%)	12 (2%)	0.47/0.79	
No	492	23 (96%)	469 (98%)		
International travel (past yea	ır)				
Yes	31	1 (4%)	30 (6%)	1/1	
No	471	23 (96%)	448 (93%)		
Lived internationally in the la	ast 5 years	5			
Yes	37	4 (17%)	33 (7%)	0.09/0.79	
No	463	20 (83%)	443 (92%)		
Exposure to treated recreation	onal water				
Yes	127	4 (17%)	123 (26%)	0.47/0.79	
No	371	20 (83%)	351 (73%)		
Exposure to untreated recrea	tional wa	ter in the past month			
Yes	107	3 (13%)	104 (22%)	0.44/0.70	
No	391	21 (88%)	370 (77%)	0.44/0.79	

802

<sup>1</sup>p-values were calculated using 'fisher.test' function in R with Monte-Carlo simulations. <sup>2</sup>FDR adjusted p-values

803 were calculated using the 'p.adjust' function in R with the Benjamini-Hochberg method.

804

## 806 Table 2: Assembled plasmids carried by each isolate identified by PlasmidFinder with encoded

## 807 antibiotic genes identified by AMRFinderPlus and encoded virulence genes identified by

## 808 VirulenceFinder. Plasmid number in each isolate matches the numbers in panels C and D of Figure 1

and Figure 2.

<i>Isolate<sup>a</sup></i>	Plasmid Type	Plasmid-associated Antibiotic Resistance Genes	Virulence Genes
497R (n=4)	1. IncI1 2. IncFII	1. bla <sub>CTX-M-1</sub>	1. cia 2. mcbA, traJ, traT
491 (n=2)	-		
498 (n=3)	1. IncFII 2. IncFIB	2. <i>bla<sub>CTX-M-27</sub></i>	1. aap, eatA, faeF, traT 2. traJ, traT
499 (n=0)	-		
497 (n=2)	1. IncF 2. IncI1	1. <i>tetA</i> , <i>tetR</i> 2. <i>bla<sub>CTX-M-1</sub></i>	1. anr, ompT 2. cia
495 (n=2)	1. IncF 2. IncF	1. $bla_{CTX-M-15}$ , $bla_{OXA-1}$ , $bla_{TEM-1}$ , $aph(3")$ -Ib, $aph(6)$ -Id, $aac(6')$ -Ib-cr5, $catB3$ , floR, qacEdelta1, qnrS1, sul1, sul2, terB, terC, terD, terE, tet(A), dfrA1	1. terC 2. anr, traJ, traT
483 (n=3)	1. IncFII 2. IncB/O/Z/K	1. bla <sub>CTX-M-15</sub> , qnrS1	1. traT 2. ireA
C483 (n=0)	-		
490 (n=3)	1. IncF	1. <i>tet</i> ( <i>B</i> )	1, anr, iucC, iutA, sitA, traT
492 (n=6)	1. IncF 2. IncFII	1. <i>bla<sub>TEM-1</sub></i> , <i>aph</i> (3")- <i>Ib</i> , <i>aph</i> (6)- <i>Id</i> , <i>sul2</i> , <i>tet</i> ( <i>B</i> ) 2. <i>bla<sub>TEM-1</sub></i>	1. anr, iucC, iutA, sitA, traT 2. mcbA, traJ, traT
504 (n=3)	1. IncF 2. IncFII	1. bla <sub>CTX-M-27</sub> , aadA5, aph(3")-Ib, aph(6)-Id, erm(B), mph(A), qacEdelta1, sul1, sul2, tet(A), dfrA17	1. senB 2. fyuA, traJ
486 (n=3)	1. IncF	1. <i>bla<sub>CTX-M-27</sub></i>	1. senB
482 (n=3)	1. IncF 2. Col156		1. traJ, traT 2. senB
505 (n=1)	1. IncF	1. bla <sub>CTX-M-27</sub> , aadA5, aph(3'')-Ib, aph(6)-Id, mph(A), qacEdelta1, sul1, sul2, tet(A), dfrA17	1. anr, senB, traT
493 (n=2)	1. IncF 2. IncF	1. bla <sub>CTX-M-27</sub> , aadA5, aph(3")-Ib, aph(6)-Id, mph(A), qacEdelta1, sul1, sul2, tet(A), dfrA17	1. anr, senB, traT 2. traT
496 (n=1)	1. IncF	1. bla <sub>TEM-1</sub> , aph(3")-Ib, aph(6)-Id, qnrS1, sul2, dfrA14	1. anr, traJ, traT
503 (n=1)	1. IncF	1. <i>tet</i> ( <i>A</i> )	1. iutA, senB
485 (n=2)	1. IncF		1. anr, iutA, senB, traJ, traT
487 (n=2)	1. IncF	1. aph(3")-Ib, aph(6)-Id, sul2, tet(A)	1. anr, senB
488 (n=3)	1. IncFI 2. IncFII	1. bla <sub>TEM-1</sub> , aadA5, aph(3")-Ib, aph(6)-Id, mph(A), qacEdelta1, sul1, sul2, tet(A), dfrA17	1. traJ, traT 2. mcbA, traT
500 (n=3)	1. IncF	1. <i>bla<sub>TEM-1</sub></i> , <i>aac</i> (3)- <i>IId</i> , <i>aadA5</i> , <i>aph</i> (3")- <i>Ib</i> , <i>aph</i> (6)- <i>Id</i> , <i>mph</i> (A), <i>qacEdelta1</i> , <i>sul1</i> , <i>sul2</i> , <i>tet</i> (A), <i>dfrA17</i>	1. senB, traJ, traT
484 (n=3)	1. IncF 2. IncFII	1. <i>bla<sub>TEM-1</sub></i> , <i>aac</i> (3)- <i>IId</i> , <i>aph</i> (3")- <i>Ib</i> , <i>aph</i> (6)- <i>Id</i> , <i>sul2</i> , <i>tet</i> ( <i>B</i> ), <i>dfrA17</i>	1. anr 2. traT
494 (n=2)	1. IncF	1. $bla_{TEM-1}$	1. anr, senB, traT
489 (n=2)	1. IncF	1. bla <sub>CTX-M-27</sub>	1. anr, senB, traT
501 (n=3)	1. IncF 2. IncI1	1. <i>bla<sub>CTX-M-27</sub></i>	1. anr, senB, traT 2. cia
502 (n=2)	1. IncF	1. <i>bla<sub>CTX-M-27</sub></i>	1. anr, senB

<sup>a</sup> n represents total number of plasmids contigs associated with each isolate, as listed in Table S5.